Business
C4 Therapeutics Appoints Veteran Biotechnology Leader Stephen Fawell, Ph.D. to Board of Directors
WATERTOWN, Mass., Sept. 03, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to
About this update from C4 Therapeutics, Inc.
[{"type":"text","content":"WATERTOWN, Mass., Sept. 03, 2024 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (Nasdaq: CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced the continued evolution of its Board of Directors with the appointment of Stephen (Steve) Fawell, Ph.D. as a director. With this appointment, Malcolm Salter has decided to retire from the Board of Directors after nearly a decade of service. “We are excited to welcome Steve to the Board of Directors and leverage his decades of experience leading discovery strategies for global pharmaceutical companies focused on designing innovative molecules, many of which have successfully moved through clinical development and achieved regulatory approval,” said Andrew Hirsch, president and chief executive officer of C4 Therapeutics. “Steve’s expertise across drug discovery and development closely aligns with our continued evolution and steadfast focus on developing degrader medicines for patients in need.” Mr. Hirsch continued, “On behalf of the Board of Directors, I would like to thank Malcolm Salter for his contributions to C4 Therapeutics. He has been a valued director since shortly after our founding in 2015 and helped us become a publicly traded company, advance several medicines into the clinic and build a culture that attracts, develops and retains top talent. I have enjoyed working with Malcolm and wish him the best in the future.” On his appointment, Steve Fawell, Ph.D. said, “I am delighted to join the Board of Directors at C4 Therapeutics after closely following the company’s approach to targeted protein degradation for quite some time. I continue to be impressed by C4 Therapeutics’ ability to design potent and selective degraders that have the potential to directly impact disease.” He added, “Now, as a director, I look forward to supporting the management team as they advance the portfolio toward pivotal milestones and bring molecules designed by C4T’s talented team dedicated to targeted protein degradation to additional patients.” Dr. Fawell has nearly 35 years of drug discovery experience spanning oncology, virology and other disease areas to successfully advance multiple investigational new drugs into clinical trials and ultimately achieve regulatory approval. Most recently, he spent more than a decade at AstraZene...